Insider Purchases: Inside the Buy
Tag: FunStock
🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.
When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.
💳 PayPal (PYPL): An 8× P/E, a CFO Insider Buy, and Why This FinTech Giant May Be Too Cheap to Ignore
PayPal has lost more than 85% of its value since 2021, yet it continues to grow revenue, generate billions in free cash flow, and aggressively repurchase shares. Has Wall Street become too pessimistic, or is PYPL a classic value trap? We examine the bull case, the risks, and what could reignite growth.
💳 Fiserv Insiders Keep Averaging Down. Wall Street Sees Trouble. Bulls See A 6x Earnings Cash Machine.
Fiserv's executives are putting their money where their mouths are. With insider buying surging, Clover processing $324 billion annually, and valuation multiples near historic lows, the payments giant has become one of Wall Street's more fascinating turnarounds.
🍩 Krispy Kreme (DNUT): The 3G Mastermind, 7-Day Squeeze Trap, and the Great Post-IPO Cash Flow Resuscitation
Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.
🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown
Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.
🚢 Norwegian Cruise Line (NCLH): Why Insiders Just Bought $27M of Stock
Norwegian Cruise Line Holdings may be more than a cruise recovery stock. With a new CEO, nearly $27 million in insider purchases, institutional ownership locking up almost the entire float, and valuation metrics that look surprisingly cheap, NCLH is turning into one of the more intriguing turnaround stories on deck.
⚡ Celsius Holdings (CELH): Wall Street Panicked. Insiders Bought the Dip
Celsius Holdings (CELH) may no longer be just a trendy fitness energy drink brand. With explosive 138% revenue growth, synchronized insider buying, Alani Nu integration success, and PepsiCo’s distribution engine accelerating expansion, the stock increasingly looks like a high-growth GARP opportunity hiding beneath a brutal valuation reset.
🚢 Norwegian Cruise Line (NCLH): Wall Street Sees Turbulence. Insiders See Opportunity
Norwegian Cruise Line (NCLH) may be one of the market’s most misunderstood recovery plays. Despite heavy debt concerns and softer guidance, insiders are buying aggressively, institutions still dominate ownership, and the stock trades at surprisingly cheap valuation levels relative to long-term earnings potential.
☕ Black Rock Coffee Bar (BRCB): The Hypergrowth Coffee Chain Wall Street May Have Oversold
Black Rock Coffee Bar (NASDAQ: BRCB) may be one of the market’s more fascinating small-cap growth stories hiding beneath a brutal selloff. With insider buying accelerating, revenue climbing nearly 24%, and profitability improving, investors are beginning to wonder whether Wall Street overshot the downside.
📈 Top 10 Insider Buys April 2026: CEOs Buying OSCR, NKE, LW & More
CEOs, directors, and 10% owners are writing real checks again. From Oscar Health’s massive $11.9M buy to Nike’s continued dip-buying, here are the most interesting insider moves of April 2026.